ClinicalTrials.gg
CompletedNCT00854100Updated Mar 5, 2019Results posted

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

A Phase 2 interventional study of Antidepressant + placebo and Antidepressant + cariprazine (0.1-0.3 mg/day) in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 41 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-05.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.

Enrollment
38th of 53
231 · median 442
Started
2009
with 4 others
Phase 2
12 of 53
1 open now
Registered
8th of 53
by date

Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 38th largest by enrollment, is one of 5 that started in 2009, is one of 12 in phase 2, and was the 8th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Depressive Disorder, Major by AbbVie, or all of them as a file.
02

Study summary

This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Adjunctive
  • Depression
  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18-65 years old
  • Currently meet the criteria for moderate to severe MDD without psychotic features.
  • Previous failure to respond to adequate trials of one or two ADTs with less than 50% reduction in depressive symptoms during the present episode.

Exclusion criteria

Exclusion Criteria:

  • based diagnosis of an axis I disorder, other than MDD, or any axis I disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
231 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo

    Drug: Antidepressant + placebo

  • Experimental
    Cariprazine 0.1 - 0.3 mg

    Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose

    Drug: Antidepressant + cariprazine (0.1-0.3 mg/day)

  • Experimental
    Cariprazine 1.0 - 2.0 mg

    Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose

    Drug: Antidepressant + cariprazine (1-2 mg/d)

Interventions

  • DrugAntidepressant + placebo

    Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.

  • DrugAntidepressant + cariprazine (0.1-0.3 mg/day)

    Drug page: Cariprazine

    Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.

  • DrugAntidepressant + cariprazine (1-2 mg/d)

    Drug page: Cariprazine

    Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity. The primary efficacy parameter was the change in MADRS score totals from the scores taken at Baseline (Week 8) and during at least one more time point up to and including Week 16.

    Time frame: Baseline (Week 8) to Week 16

Secondary outcomes

  1. Clinical Global Impression - Improvement (CGI-I)

    The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale that, in this study, will be used to rate total improvement or worsening of mental illness starting at Visit 2 (Week 2) and taken at every visit through Visit 11 (Week 16). The patient will be rated on a scale from 1 to 7, 1 indicating that the patient is very much improved and 7 indicating that the patient is very much worse. The secondary efficacy parameter was the CGI-I total score at Week 16.

    Time frame: Week 16

07

Results

Posted Mar 5, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mg
Started817674
Completed727063
Not completed9611
Withdrew: Inability to complete the study visits001
Withdrew: Lost to follow-up203
Withdrew: Withdrawal by subject312
Withdrew: Protocol violation243
Withdrew: Adverse event212

Outcome measures

PrimaryMontgomery-Asberg Depression Rating Scale (MADRS)

The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity. The primary efficacy parameter was the change in MADRS score totals from the scores taken at Baseline (Week 8) and during at least one more time point up to and including Week 16.

Time frame:
Baseline (Week 8) to Week 16
Reported as:
Least squares mean · Units on a Scale
Montgomery-Asberg Depression Rating Scale (MADRS)
Units on a ScalePlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mg
Montgomery-Asberg Depression Rating Scale (MADRS)-8.0 ± 1.0-7.5 ± 1.1-9.8 ± 1.1
Statistical analysis
  • Placebo vs Cariprazine 0.1 - 0.3 mg · ANCOVA · p = 0.746 · Least squares mean difference: 0.5 · 95% CI -2.4 to 3.4
  • Placebo vs Cariprazine 1.0 - 2.0 mg · ANCOVA · p = 0.227 · Least squares mean difference: -1.8 · 95% CI -4.8 to 1.1
SecondaryClinical Global Impression - Improvement (CGI-I)

The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale that, in this study, will be used to rate total improvement or worsening of mental illness starting at Visit 2 (Week 2) and taken at every visit through Visit 11 (Week 16). The patient will be rated on a scale from 1 to 7, 1 indicating that the patient is very much improved and 7 indicating that the patient is very much worse. The secondary efficacy parameter was the CGI-I total score at Week 16.

Time frame:
Week 16
Reported as:
Least squares mean · Units on a Scale
Clinical Global Impression - Improvement (CGI-I)
Units on a ScalePlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mg
Clinical Global Impression - Improvement (CGI-I)2.5 ± 0.12.5 ± 0.12.3 ± 0.1
Statistical analysis
  • Placebo vs Cariprazine 0.1 - 0.3 mg · ANCOVA · p = 0.918 · Least squares mean difference: 0.0 · 95% CI -0.3 to 0.3
  • Placebo vs Cariprazine 1.0 - 2.0 mg · ANCOVA · p = 0.167 · Least squares mean difference: -0.2 · 95% CI -0.6 to 0.1

Adverse events

Collected over Up to 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prospective Antidepressant-Therapy Lead In Period1/502 (0.2%)9/502 (1.8%)262/502 (52.2%)
Placebo0/81 (0%)1/81 (1.2%)32/81 (39.5%)
Cariprazine 0.1 - 0.3 mg0/76 (0%)0/76 (0%)29/76 (38.2%)
Cariprazine 1.0 - 2.0 mg0/73 (0%)1/73 (1.4%)35/73 (47.9%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventProspective Antidepressant-Therapy Lead In PeriodPlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mg
Chronic Obstructive Pulmanary DiseaseRespiratory, thoracic and mediastinal disorders0/5020/810/761/73
Angina UnstableCardiac disorders0/5021/810/760/73
Suicidal IdeationPsychiatric disorders2/5020/810/760/73
AnxietyPsychiatric disorders1/5020/810/760/73
Hip FractureInjury, poisoning and procedural complications1/5020/810/760/73
Road Traffic AccidentInjury, poisoning and procedural complications1/5020/810/760/73
Upper Limb FractureInjury, poisoning and procedural complications1/5020/810/760/73
DepressionPsychiatric disorders1/5020/810/760/73
ConvulsionNervous system disorders1/5020/810/760/73
Serotonin SyndromeNervous system disorders1/5020/810/760/73
Most frequent other events
Showing 10 of 17
Most frequent other events
EventProspective Antidepressant-Therapy Lead In PeriodPlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mg
HeadacheNervous system disorders73/5023/818/766/73
NauseaGastrointestinal disorders70/5025/815/765/73
InsomniaPsychiatric disorders60/5023/812/767/73
Dry MouthGastrointestinal disorders53/5021/812/764/73
RestlessnessPsychiatric disorders0/5021/811/767/73
DizzinessNervous system disorders31/5027/814/766/73
NasopharyngitisInfections and infestations0/5025/811/766/73
FatigueGeneral disorders36/5023/812/765/73
DiarrhoeaGastrointestinal disorders36/5025/814/763/73
ConstipationGastrointestinal disorders35/5021/811/764/73

Baseline characteristics

A total of 231 patients were eligible for randomization to double-blind treatment; 230 patients were randomized and received at least 1 dose of treatment (Double-blind Safety Population)

Age, Continuous
Age, Continuous(Years)PlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mgTotal
Mean45.2 ± 10.246.6 ± 11.744.2 ± 12.145.3 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mgTotal
Female615251164
Male20242266
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mgTotal
Hispanic or Latino79925
Not Hispanic or Latino746764205
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCariprazine 0.1 - 0.3 mgCariprazine 1.0 - 2.0 mgTotal
American Indian or Alaska Native2002
Asian0213
Native Hawaiian or Other Pacific Islander0000
Black or African American10151136
White695760186
More than one race0213
Unknown or Not Reported0000
08

Study locations

41 sites
  • Forest Investigative Site 040
    Phoenix, Arizona 85050, United States
  • Forest Investigative Site 038
    Scottsdale, Arizona 85254, United States
  • Forest Investigative Site
    Arcadia, California 91007, United States
  • Forest Investigative Site
    Encino, California 91316, United States
  • Forest Investigative Site
    Garden Grove, California 92845, United States
  • Forest Investigative Site
    Irvine, California 92618, United States
  • Forest Investigative Site 013
    Los Alamitos, California 90720, United States
  • Forest Investigative Site 041
    National City, California 91950, United States
  • Forest Investigative Site
    Oceanside, California 92056, United States
  • Forest Investigative Site 025
    Denver, Colorado 80239, United States
  • Forest Investigative Site
    Norwich, Connecticut 06360, United States
  • Forest Investigative Site
    Washington, District of Columbia 20016, United States
  • Forest Investigative Site 007
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site 012
    West Palm Beach, Florida 33407, United States
  • Forest Investigative Site 033
    Atlanta, Georgia 30306, United States
  • Forest Investigative Site
    Roswell, Georgia 30076, United States
  • Forest Investigative Site
    Overland Park, Kansas 66211, United States
  • Forest Investigative Site 042
    Fall River, Massachusetts 02721, United States
  • Forest Investigative Site 034
    Pittsfield, Massachusetts 01267, United States
  • Forest Investigative Site
    Omaha, Nebraska 68131, United States
  • Forest Investigative Site
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site 001
    Bronx, New York 10467, United States
  • Forest Investigative Site 043
    Brooklyn, New York 11235, United States
  • Forest Investigative Site 020
    Mount Kisco, New York 10549, United States
  • Forest Investigative Site 039
    New York, New York 10003, United States
  • Forest Investigative Site 029
    New York, New York 10021, United States
  • Forest Investigative Site 032
    Raleigh, North Carolina 27607, United States
  • Forest Investigative Site
    Canton, Ohio 44718, United States
  • Forest Investigative Site
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 015
    Portland, Oregon 97210, United States
  • Forest Investigative Site 006
    Media, Pennsylvania 19063, United States
  • Forest Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Forest Investigative Site
    Philadelphia, Pennsylvania 19107, United States
  • Forest Investigative Site 023
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 031
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site
    Nashville, Tennessee 37212, United States
  • Forest Investigative Site
    San Antonio, Texas 78229, United States
  • Forest Investigative Site
    Woodstock, Vermont 05091, United States
  • Forest Investigative Site
    Richmond, Virginia 23230, United States
  • Forest Investigative Site
    Bellevue, Washington 98007, United States
  • Forest Investigative Site
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I, Nemeth G. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018 Nov;33(6):312-321. doi: 10.1097/YIC.0000000000000235. PubMed 30045066 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2009 to primary completion in Dec 2010, 17 months.

Results were first posted in Mar 2019, 8 years 2 months after primary completion. A results delay was requested in Feb 2012.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 17 months is close to that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2009
First posted
Mar 2, 2009
StartActual
Jun 30, 2009
Primary completionActual
Dec 6, 2010
CompletionActual
Dec 6, 2010
Results delay requested
Feb 6, 2012
Results first posted
Mar 5, 2019
Last update
Mar 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00854100
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Mar 2, 2009
Start date
Jun 30, 2009
Primary completion
Dec 6, 2010
Completion
Dec 6, 2010
Results posted
Mar 5, 2019
Last update
Mar 5, 2019

Study contacts

Robert Hayes, PhD
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion